Company intelligence / Profile preview
Lisata Therapeutics
- Ownership
- Public · LSTA
- Development stage
- Phase 2
Overview
Lead candidate certepetide has demonstrated favorable safety, tolerability, and activity in clinical trials as an enhancer of standard-of-care chemotherapy for pancreatic cancer. Multiple ongoing Phase I/II trials are evaluating its ability to improve drug delivery and outcomes in various advanced solid tumor indications. Key data readouts are expected throughout late 2025.[7][8]
- Therapeutic areas
- Oncology
- Modalities
- Cyclic peptides (notably certepetide)Drug delivery enhancers for anti-cancer drugs (enabling small molecules, immunotherapies, RNA-based therapeutics)[6][10]
- Industry
- Biotech
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $16.9M
- Total revenue
- $0
- Enterprise value
- $6.5M
Beyond the preview
Go deeper on Lisata Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lisata Therapeutics.